Navigation Links
Researcher Receives Free C6 Flow Cytometer(R) System as First Winner of Accuri Flow Cytometer(R) Creativity Awards Program
Date:12/11/2008

-Accuri Is Awarding a Free Bench-Top Flow Cytometer System Twice Yearly to Support Innovative Research and Expand the Use of Flow Cytometry-

-Learn More about the Revolutionary Accuri C6 Flow Cytometer at the American Society for Cell Biology Annual Meeting-

ANN ARBOR, Mich., Dec. 11 /PRNewswire/ -- Accuri Cytometers Inc., a life sciences company developing revolutionary bench-top flow cytometer systems, today announced the first recipient of its Accuri Flow Cytometer Creativity Awards program. Heather Newkirk, Ph.D., Executive Director of Business Development and Quality Assurance/Regulatory Affairs at Clinical Reference Laboratory, Inc. and an Assistant Professor of Medicine at the University of Missouri-Kansas City, will receive a free Accuri C6 Flow Cytometer(R) System. Accuri's twice-yearly Creativity Awards program was created to foster innovative research that taps the unrealized potential of flow cytometry and expands its use to novel applications that are newly possible as a result of the unique capabilities of the Accuri C6 system.

(Photo: http://www.newscom.com/cgi-bin/prnh/20081211/NY51523 )

Explicitly designed for routine use by biomedical researchers in their own labs, Accuri's C6 Flow Cytometer is a full-featured bench-top cell analysis system that provides capabilities similar to industry leaders in a more user-friendly format and at a fraction of the cost of other flow cytometers.

"We are gratified by the quality and creativity of this first group of research proposals for our Creativity Awards program," said Grant Howes, an industry veteran who recently joined Accuri as Director of Marketing. "A key driver behind the development of the C6 system was our belief that the research power of flow cytometry has been hampered by its lack of wide accessibility. The diverse and imaginative responses to the first round of our Awards program provide concrete evidence that our accessible, affordable flow cytometer system can help unleash the full potential of flow cytometry."

Accuri designed the revolutionary C6 system from the ground up with input from hundreds of researchers who use flow cytometry, and it specially commissioned the easy-to-use cell analysis software that is a critical component of the approach. Accuri's innovations, coupled with its state-of-the-art components, result in a cytometer that is powerful, robust, compact and affordable, at less than one-third the cost of the current market leader.

Dr. Newkirk, the recipient of the first C6 Flow Cytometer System awarded by Accuri's Creativity Awards program, plans to use bead-based assays to detect direct genomic translocations, an approach that could be applied to a myriad of genomic rearrangements, including detecting specific translocations in certain cancers. She noted, "Flow cytometry offers researchers the chance to innovate in the design of a variety of assays, and I am excited by the opportunity to develop new assays to be performed on the C6 flow cytometer. It is encouraging to see that flow cytometry has been translated into a user-friendly, lower-cost system with the invention of the C6."

Dr. Newkirk will receive her C6 system early in 2009. It will be hers to keep, along with a year-long warranty as part of the award.

Jennifer Baird, CEO of Accuri, commented, "We are delighted to announce our first Accuri Flow Cytometer Creativity Awards winner. Dr. Newkirk's genomics research proposal is a fitting illustration of why we believe that the versatility and accessibility of our flow cytometer system will generate innovative research and a host of creative applications. We congratulate her and her team and look forward to seeing the fruits of their research, as well as many more proposals from researchers around the globe."

Learn more about the Accuri C6 Flow Cytometer System and the company's next upcoming Creativity Awards grant by visiting Booth 2023 at the 48th Annual Meeting of the American Society for Cell Biology in San Francisco from December 13-17, 2008, or at www.AccuriCytometers.com. Accuri Cytometers: Cell Analysis Within Reach(R).

About Accuri Cytometers

Accuri Cytometers, Inc. is an Ann Arbor-based life sciences company developing and marketing revolutionary high performance cell analysis systems designed to bring the power of flow cytometry into the labs of life sciences researchers everywhere. Reflecting the input of hundreds of researchers, the Accuri C6 Flow Cytometer(R) is a full-featured bench-top cell and bead analysis system that provides similar capabilities to those of industry-leading flow cytometers in an easy-to-use format and at a fraction of their cost. The Accuri system was engineered from the start to be compact, powerful and user-friendly, while also being affordable by most research laboratories. For more information, visit www.AccuriCytometers.com.

About Clinical Reference Laboratory

Established in 1979, Clinical Reference Laboratory, Inc. offers leading-edge testing services in the areas of Molecular Diagnostics, Clinical Trials, Toxicology, Insurance and Wellness testing. With a comprehensive test menu ranging from routine laboratory services to the latest in molecular testing, we are committed to providing high-quality science with a human touch. For more information, visit www.crlcorp.com

    For additional information, contact:
    Accuri Cytometers
    Jack Ball
    Chief Commercial Officer
    (734) 994-8000

    Media
    GendeLLindheim BioCom Partners
    Barbara Lindheim
    (212) 918-4650


'/>"/>
SOURCE Accuri Cytometers Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. UBC researchers discover gene mutation that causes eye cancer
2. Researchers report on convergence of technology
3. Einstein researchers discover protein that contributes to cancer spread
4. Researchers & Department of Defense Question Multiple Vaccine Administration
5. Researchers gain new insight on wonder of cell division
6. HALT-C researchers: Interferon as long-term treatment for hepatitis C not effective
7. Jefferson researcher awarded NIH grant
8. Researcher develops screening tool to identify patients with prediabetes
9. LA BioMed researchers among Southern California Super Doctors
10. Researchers discover new enzyme in cancer growth
11. Researchers identify cell group key to Lyme disease arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... March 24, 2017 , ... Vighter established its NAEMT Authorized ... providing Prehospital Trauma Life Support (PHTLS) course scholarships to four medics assigned to ... developed in cooperation with the American College of Surgeons to promote critical thinking ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... world countries to hospitals in the United States, it’s a threat that is ... current obstacles facing infection prevention and offers strategies for the healthcare community to ...
(Date:3/24/2017)... Farifax, VA (PRWEB) , ... March 24, 2017 , ... ... its 2017 Quest Awards . The annual awards, now in their 12th year, ... marketing peers selects the winners. , In 2016, the awards were retooled to recognize ...
(Date:3/24/2017)... ... , ... Texas Physical Therapy Specialists (TexPTS) is pleased to announce the ... clinic is the group’s 7th location in San Antonio and 23rd in Texas. ... care from the clinic, which opened March 22, 2017. , The team ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... related services to families and business owners across eastern Michigan, is connecting with ... families struggling with financial difficulties. , The Oxford/Orion FISH Food Pantry works to ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... LONDON , March 23, 2017 ... comprehensive research report created through extensive primary research ... research, the report aims to present the analysis ... basis of Procedure (Replacement and Repair); Replacement Procedure ... (TAVR)), Repair By Technique (Surgical Devices, Balloon Valvuloplasty, ...
(Date:3/23/2017)... 23, 2017  The U.S. Food and Drug Administration ... treatment of adults and pediatric patients 12 years and ... who have not received prior chemotherapy. This is the ... form of skin cancer. "While skin cancer ... a rare form called Merkel cell cancer have not ...
(Date:3/23/2017)... SAN DIEGO and VANCOUVER, British ... Inc. (NASDAQ: SPHS ) (the "Company" or ... for the treatment of urological diseases, today announced that ... which evaluated the drug as a focal treatment for ... on March 26, 2017 at the 32 nd ...
Breaking Medicine Technology: